The Effect of Bevacizumab on Human Tenon Fibroblasts in Ocular Wound Healing

We have read the paper “Antifibrotic Activity of Bevacizumab of Human Tenon's Fibroblasts In Vitro” of O'Neill et al. ¹ (published in Recently Accepted Papers on June 23, 2010) with great interest. We would like to thank the authors for their interesting work and for referring to our paper. ²  

Unfortunately, our work has been erroneously cited with regard to the following points: 

In the discussion of their paper (page 13, 2nd paragraph) the authors mention:

 

Li et al.³⁹ found a single dose of 0.75 mg bevacizumab (0.03 mL of 25 mg/mL) given immediately after surgery significantly reduced the density of blood vessels and the number of inflammatory cells during the early stages of wound healing and reduced the collagen deposition in the later stages.

1.  
   We injected a total volume of 300 μL (0.3 mL) instead of 0.03 mL; therefore, the dose and volume should be changed to: “… a single dose of 7.5 mg bevacizumab (0.3 mL of 25 mg/mL)… .”
2.  
   We never observed (or reported) an effect of inflammation after a single injection of bevacizumab; therefore, the phrase “… and the number of inflammatory cells…” should be removed.

Therefore, we feel that this statement should be changed as follows:

 

Li et al.³⁹ found that a single dose of 7.5 mg bevacizumab (0.3 mL of 25 mg/mL) given immediately after surgery significantly reduced the density of blood vessels during the early stages of wound healing and reduced the collagen deposition in the later stages.

 

Once again, we are delighted that the authors cited our work, but we would greatly appreciate having these corrections conveyed to the readers.